Clinical Trial Search

Primary: Percentage of Participants With Successful Ring Insertion — 100; 100 Percentage of participants

Primary: Changes From Baseline in the Post Coital Test Results (PCT) Due to Device Use. — 0; 26 Participants

Primary: Quantity of BV-associated Bacteria by qPCR and High-throughput Sequencing Tests — 5.59; 5.22; 4.91; 7.41 log10 copies/ml — p=0.011

Primary: Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported. — 0.01; -0.005; -0.02; .007 mm

Primary: Adherence Rate (Rate of Perfect Method Use) — 57; 45 Percentage of Participants — p=0.05

Primary: Number of Participants With Regular Menstrual Cycles — 192; 9; 3; 199 Participants

Primary: Contraceptive Efficacy Using the Pearl Index for All Subjects — 2.96 Number of pregnancies per 100 women mths

Primary: Number of Days Bleeding is Reported. — 34.0; 42.1; 39.8; 14.7 Days

Primary: Percentage of Applicator Users Who Were Very Satisfied and Satisfied- User Satisfaction Questionnaire for Domain: Design & Technical Aspects — 99.1 Percentage of…

Primary: Change From Baseline in Mean Menstrual Cramping Pain Score Through Cycle 2 — -1.7; -1.7; -1.9; -1.7 Units on a scale — p=< 0.001

Primary: Number of Participants Choosing Each Hormonal Contraceptive Method Before and After Counseling — 1207; 1199; 60; 131 Participants — p=0.705

Primary: Mean Number of Bleeding or Spotting Days — 16; 28 days

Primary: Efficacy of VR101 Treatments at 28 Days Assessed by Change in VHI (Vaginal Health Index) Scores Assigned by Clinicians — 1.76; 0.55; 1.38; 0.97 Score on a Scale

Primary: Number of Participants That Successfully Insert Vaginal Film — 8; 8; 22; 22 Participants — p=>.99

Primary: Proportion of Participants With Increased Female Sexual Function Index Lubrication Domain (FSFI-LD) Scores — 57; 43 Participants

Primary: Percentage of Participants With Ovulation Incidence, by Cycle — 0; 0; 0; 0 Percentage of Participants

Primary: Etonogestrel Concentrations at Study Day 21 — 1860.00; 429.00; 3290.00 pg/mL — p=<0.001

Primary: Grade 1 Genitourinary Events or Higher as Defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events — 7; 1 Adverse events

Primary: Number of Participants With Implant Continuation — 219; 225 Participants

Primary: Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. — 71; 97 Participants

Primary: The Safety of Dapivirine (25 mg) Administered Via a Silicone Vaginal Ring in HIV-uninfected Adolescent Females, When Inserted Once Every 4 Weeks During 24 Weeks of Study…

Primary: HIV-1 Seroconversion According to Comprehensive HIV Testing Algorithm. — 82; 61 Participants

Primary: Number of Colposcopic Findings (Baseline and After One Week of Product Use) — 3; 0; 2; 0 colposcopic findings — p=0.4870

Primary: Pearl Index, by Treatment Group — 1.92; 3.12 Pregnancies per 100 woman-years — p=0.531

Primary: Number of Participants With Ovulation With Implant-alone — 7; 0 Participants

Primary: Patient-reported Pain at Passage of Insertion Device Through Cervix, as Measured on a 100 mm VAS — 55.8; 53.9 mm

Primary: Contraceptive Method Discontinuation — 300; 62; 142 Participants

Primary: The Safety Profile of the 25 mg Dapivirine Vaginal Ring-004, When Inserted at Monthly Intervals. Participants Attended RC at Monthly Visits (up to Max of Three Monthly…

Primary: Change in Pain From Baseline to IUD Insertion — 61; 68 change in visual analog scale score

Primary: The Safety Profile Associated With the Open-label Use of the Dapivirine Vaginal Matrix Ring (25 mg) in Women — 52; 19; 2 Participants